AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Previously Presented) A compound of the general formula (I):



(I)

wherein

A is a heteroalkyl-, heterocycloalkyl-, heteroalkyl-cycloalkyl-, heteroaryl- or heteroarylalkyl group,

G-E is selected from the following groups,

or is part of an optionally substituted cyclopropyl ring,

n is 0, 1 or 2,

R^1 is a C_1-C_4 alkyl- or a C_3-C_4-cycloalkyl group,

X is oxygen or a group of the formula NR^2, wherein R^2 is hydrogen, OH, NH_2, NH(Alkyl), N(alkyl)$_2$, a alkyl-, alkenyl-, alkynyl-, hetero-alkyl-, aryl-, heteroaryl-, cycloalkyl-, alkylcyclo-alkyl-, heteroalkylcycloalkyl-, heterocycloalkyl-, aralkyl- or a heteroaralkyl group,

R^3 and R^4 are independently of each other hydrogen, a C_1-C_4 alkyl group or together are part of a cycloalkyl group with 3 or 4 ring atoms,

or a pharmacologically acceptable salt, solvate, hydrate or a pharmacologically acceptable formulation thereof.

2. (Previously Presented) A compound according to claim 1, wherein A is a group of the formula $-C(CH_3)=CHR^5$, $-C(C_2H_5)=CHR^5$, $-C(Cl)=CHR^5$ or $-CH=CHR^5$, wherein R^5 is a heteroaryl- or a heteroarylalkyl group.

3. (Previously Presented) A compound according to claim 1, wherein A is a group of the general formula (II), (III), (IV), or (V):



(II)



(III)



IV



V

wherein

Q is sulphur, oxygen or a group of the formula NR^7, wherein R^7 is hydrogen, a C_1-C_4 alkyl group or a C_1-C_4-heteroalkyl group, z is nitrogen or a CH group and R^6 is a group of the formula OR^8 or NHR^8, a alkyl-, alkenyl, alkinyl- or a heteroalkyl group, wherein R^8 is hydrogen, a C_1-C_4-alkyl group or a C_1-C_4-heteroalkyl group.

4. (Previously Presented) A compound according to claim 3, wherein z is a CH-group.

5. (Previously Presented) A compound according to claim 3, wherein Q is sulphur or oxygen.

6. (Previously Presented) A compound according to claim 3, wherein R^6 is a group of the formula CH_3, CH_2OH or CH_2NH_2.

7. (Previously Presented) A compound according to claim 1, wherein X is oxygen.

8. (Previously Presented) A compound according to claim 1, wherein R^1 is a methyl group.

9. (Previously Presented) A compound according to claim 1, wherein R^3 and R^4 are methyl groups.

10. (Currently Amended) A method of synthesizing the compound of claim 1 comprising ~~the use of~~ (a) coupling (i) (1,1-Dialkyl-2-oxo-butylsulfanyl)-acetic acid or ~~its derivatives as an intermediate, wherein the derivatives are~~ a derivative thereof selected from the group consisting of sulfoxides, sulfones, esters, amides, 3-haloderivates, (3-bromo-1,1-dimethyl-2-oxo-butylsulfanyl)-acetic acid esters of methanol and ethanol, and sulfoxides of methanol and ethanol to (ii) a compound selected from the group consisting of (1E,5Z,3S,10S)-11-(tert-butyl-dimethylsilyloxy)-2,6,10-trimethyl-1-(2-methyl-thiazol-4-yl)-undeca-1,5-dien-3-ol, (1E,5Z,3S,10S)-11-(tert-butyl-dimethyl-silyloxy)-2,6,10-trimethyl-1-(2-methyloxazol-4-yl)-undeca-1,5-dien-3-ol, and (1E,5Z,3S,10S)-11-(tert-butyl-dimethyl-silyloxy)-2,6,10-trimethyl-1-(2-methyl-pyridine-2-yl)-undeca-1,5,9-trien-3-ol via an esterification reaction, and (b) subjecting the product of step (a) to an aldol condensation reaction, to synthesize the compound of claim 1,.

11. (Previously Presented) A pharmaceutical composition containing a compound according to claim 1 and optionally a carrier and/or adjuvants.

12. (Previously Presented) A method of treating cancer in a human comprising administering the compound of claim 1 to the human.

13. (Previously Presented) A method of treating cancer in a human comprising administering the pharmaceutical composition of claim 11 to the human.